Warfarin Pharmacogenetics: Pharmacogenetic Optimization of Anticoagulant Response (POAT) and Genetic and Environmental Determinants of Warfarin Response (GEDWR)
Anthropometry (2)
- height - Height in centimeters (phv00200370.v1.p1)
- weight - Weight in kilograms (phv00200369.v1.p1)
Biomarkers (2)
- ckd1_1 - Glomerular filtration rate (GFR) was estimated by using the 4-variable MDRD Study equation. If GFR>30<60 then CKD1_1=1 else CKD1_1=0. (phv00200372.v1.p1)
- ckd1_2 - Glomerular filtration rate (GFR) was estimated by using the 4-variable MDRD Study equation. If GFR<30 then CKD1_2=1; else CKD1_2=0. (phv00200373.v1.p1)
Demographics (2)
- aged - Age in decades (age/10) (phv00200368.v1.p1)
- sex - Gender (phv00200366.v1.p1)
Disease Events (1)
- rfchf - Congestive Heart failure; Comorbid condition/ risk factor for adverse events (phv00200371.v1.p1)
Medications (3)
- amiod - Amiodarone co-therapy (phv00200374.v1.p1)
- aspirin - Aspirin co-therapy (phv00200375.v1.p1)
- Dose_stable - Stable warfarin dose (mg/week) was defined as the dose (with up to a 10% change) that resulted in a therapeutic INR between 1.8 and 3.2 for at least 3 consecutive clinic visits at least two weeks apart (phv00200367.v1.p1)
Other (10)
- ANALYTE_TYPE - Analyte Type (phv00200378.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00200377.v1.p1)
- CONSENT - Consent group (phv00200361.v1.p1)
- GENOTYPING_CENTER - Name of the center which conducted genotyping (phv00200379.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00200376.v1.p1)
- SAMPLE_ID - Sample ID (phv00200363.v1.p1)
- SAMPLE_USE - Sample Use (phv00200364.v1.p1)
- SUBJECT_ID - Identification number (phv00200365.v1.p1)
- SUBJECT_ID - Subject ID (phv00200362.v1.p1)
- SUBJECT_ID - Subject ID (phv00200360.v1.p1)